The first Italian accelerator dedicated to biotech companies has been launched by European venture capital firm Sofinnova Partners.
BiovelocITA aims to accelerate research projects to proof of concept and then transform them into biotech companies.
The new venture, which brings together best-in-class scientists, entrepreneurs and investors, was co-founded and will be managed by Italian entrepreneurs Silvano Spinelli and Gabriella Camboni.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze